Daxor Corporation - SIC # 8081 -

Ticker Exchange SIC # Website Latest Ticker
DXR Nasdaq 8081 www.daxor.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Daxor Corporation

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center - Apr 8th, 2026 6:00 am
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 - Mar 26th, 2026 6:00 am
Dynamic announces March 2026 cash distributions for Dynamic Active ETFs and ETF Series - Mar 19th, 2026 7:00 am
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions - Mar 17th, 2026 6:00 am
Daxor Details Portable FDA-Cleared Blood Volume Analyzer, 'Razor-and-Blades' Kit Growth at iAccess Alpha - Mar 15th, 2026 9:15 am
Updated Lineup Announced for the iAccess Alpha Virtual Best Ideas Spring Investment Conference March 10-11, 2026 - Mar 10th, 2026 7:00 am
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress - Mar 10th, 2026 6:00 am
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 - Mar 9th, 2026 6:00 am
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - Mar 3rd, 2026 6:30 am
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - Mar 3rd, 2026 6:00 am
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee - Feb 24th, 2026 6:00 am
Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business - Feb 10th, 2026 6:00 am
Daxor Corporation Announces $9 Million Registered Direct Offering - Jan 23rd, 2026 6:00 am
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer - Nov 25th, 2025 6:00 am
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit - Oct 21st, 2025 6:00 am
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25 - Oct 15th, 2025 6:00 am
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA - Sep 30th, 2025 6:00 am
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting - Sep 23rd, 2025 6:00 am
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care - Sep 4th, 2025 6:00 am
Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 3rd, 2025 6:00 am